Orthosilicic Acid (ch-OSA).
Bioavailable silicon. Hair, skin, nails, bones. Silicon in the form your gut can actually absorb. It supports the collagen and connective tissue framework sitting under your hair, skin, nails and bones.
Reviewed March 2026
- Category
- Mineral
- Also filed under
- HairNailsCollagen
What Orthosilicic Acid (ch-OSA) is, and what it does.
- Does it work
- Suits people focused on hair and nail quality, and anyone whose diet is light on whole grains and vegetables, which are where everyday silicon comes from.
- How much to take
- Start with 5mg to 10mg of silicon a day in water. That band is where the choline-stabilised liquid does its work. The 25mg figure is a research condition, not a daily target.
- Time to feel it
- Nothing acute. Hair and nail changes track growth rate, so give it 8 to 20 weeks before there is anything visible at the nail edge or in hair texture.
- The first dose
- Day one is a few drops in water with no sensation attached. Urinary silicon rises within hours, which is how absorption gets measured, and it is the only same-day change.
- With regular use
- Most effects take 2-8 weeks. Be patient.
- How well tolerated
- Generally well tolerated. Check with your doctor if on medications.
- How it feels
- Hair may feel thicker. Nails stronger. Takes 3-6 months.
- The overlooked benefit
- Silicic acid binds aluminium in solution into poorly absorbed complexes. That is plain inorganic chemistry and it almost never gets mentioned on a label.
5 to 10mg a day is where Orthosilicic Acid (ch-OSA) works.
Source: Barel et al., 2005; Wickett et al., 2007; BioSil brand clinical data
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 12 human trials.
- Silicon absorption from the single-molecule formRandomised trial
- Hair strength and nail qualityRandomised trial
- Skin surface condition and firmnessRandomised trial
- Bone matrix and collagen turnover markersRandomised trial
- Silicon distribution in connective tissueNarrative review
Questions people ask about Orthosilicic Acid (ch-OSA).
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Orthosilicic acid polymerises quickly in water unless it is stabilised, and choline is the standard stabiliser used to keep it in the bioavailable monomeric form. The pairing is what makes the ingredient work at all.
Silicon is associated with the crosslinking and stability of the collagen network, while peptides supply the glycine and proline building blocks. The two act on supply and on assembly of the same tissue.
Prolyl and lysyl hydroxylase need ascorbate to mature collagen strands. Silicon support means little without the cofactor that lets collagen crosslink normally.
Lysyl oxidase is a copper enzyme and it forms the covalent crosslinks that give collagen and elastin their strength. Copper status sets the ceiling on what silicon-supported matrix synthesis can achieve.
MSM supplies sulfur for the disulfide bonds in keratin while silicon supports the collagen scaffold beneath it. Hair, skin and nail formulas pair them for the two different structural proteins.
Bone is mineral deposited onto a collagen scaffold, so silicon works on the organic template and calcium on the mineral phase. They occupy complementary halves of normal bone formation.
Vitamin D governs calcium uptake and osteoblast activity, the cells that lay down the collagen matrix silicon supports. The two act on the same bone-building sequence at different steps.
Marine collagen peptides deliver the amino acid pattern of type I collagen, the exact fibre silicon is associated with stabilising in skin and bone.
Boron and silicon are grouped together as ultratrace elements with described roles in connective tissue and bone matrix formation rather than in mineral density directly. They are frequently combined in bone formulas on that basis. The pairing is mechanistic and has not been isolated in a combination trial here.
About half of body magnesium sits in bone, and it is a cofactor for the ATP-dependent steps of matrix synthesis. Silicon is associated with the collagen scaffold that mineral is laid onto. The two act on different parts of the same tissue, which is why they co-occur in bone formulas.
Glycosyltransferase enzymes require manganese to assemble the glycosaminoglycan chains of cartilage and bone matrix proteoglycans. Silicon is associated with the same extracellular matrix compartment. The manganese half of this is settled biochemistry; the silicon half is an association drawn from tissue distribution work.
Alkaline phosphatase, a zinc metalloenzyme, is central to normal bone matrix mineralisation and is the marker most often read in bone turnover work. Silicon is associated with collagen and matrix formation. Both sit in normal connective tissue maintenance by separate enzymatic routes.
Vitamin K-dependent carboxylation converts osteocalcin into its calcium-binding form, which is how that matrix protein incorporates mineral. Silicon is associated with the collagenous scaffold rather than with carboxylation. The two address different steps of matrix maturation, which is the rationale for combining them.
Roughly one residue in four of collagen is proline or hydroxyproline, and the hydroxyproline is made by post-translational hydroxylation of proline already in the chain. Silicon is associated with collagen formation in connective tissue studies. Supplying the amino acid substrate and the trace element are separate contributions to the same structural protein.
The repeating glycine-X-Y motif is what allows the three collagen chains to pack into a helix, so glycine is not optional in collagen synthesis. It is the single most abundant residue in the protein. Pairing it with a silicon source addresses substrate and trace element separately.
Lysyl oxidase acts on lysine residues to initiate the cross-links between collagen molecules, and hydroxylysine also carries the sugar attachment sites. That cross-linking step is where copper and silicon are both discussed in connective tissue literature. The amino acid role itself is textbook.
Hyaluronan is a major space-filling glycosaminoglycan of skin and joint matrix, while silicon is associated with the collagen and proteoglycan scaffold around it. They are combined in skin and joint formulas on the basis of shared tissue compartment rather than a shared enzyme. Oral hyaluronan is itself depolymerised before absorption, which is worth stating alongside the pairing.
Biotin serves as the covalently bound cofactor of the carboxylase enzymes involved in fatty acid and amino acid metabolism, which is why it appears in keratin-focused products. Silicon is discussed in the same product category on the basis of nail and hair measurements. The combination is formulation convention with distinct underlying mechanisms.
Strontium is chemically similar to calcium and is incorporated into the hydroxyapatite lattice in its place, which also inflates bone density readings on X-ray absorptiometry because strontium attenuates more strongly. Silicon sits on the matrix side rather than the mineral side. The pairing appears in bone formulas; the measurement artefact is the part worth knowing.
Bone mineral is calcium phosphate in the hydroxyapatite form, so phosphate availability is part of normal mineralisation alongside calcium. Silicon is associated with the organic matrix that mineral is deposited onto. Most diets already supply ample phosphorus, which limits how meaningful adding more is.
Nothing specific on file for Orthosilicic Acid (ch-OSA). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Orthosilicic Acid (ch-OSA) actually does.
Orthosilicic acid, Si(OH)4, is the only form of silicon absorbed to any meaningful extent from the gut. Polymerised and particulate silica must first depolymerise to the monomer before absorption can occur.
Orthosilicic acid is unstable in concentrated solution: above roughly two millimolar it condenses into oligomers and then into insoluble silica gel, which is the central formulation problem for any liquid silicon product.
Choline stabilisation works by keeping orthosilicic acid monomeric in a concentrated liquid, which is why the choline-stabilised form is described as ch-OSA rather than as plain silicic acid.
Absorbed silicon circulates largely as undissociated orthosilicic acid, is not appreciably protein-bound, and is cleared by the kidney, so urinary silicon rises and falls quickly after an oral dose.
Where Orthosilicic Acid (ch-OSA) comes from.
It starts as sand or a silicate mineral, which is chemically opened up into a soluble form and then diluted carefully into single-molecule silicic acid. That single-molecule form wants to clump back into gel, so something is added to hold it apart, and choline is what does that in the ch-OSA version. The plant-based route is different: it pulls silica out of a plant like horsetail, where most of it is already clumped.
From a mineral source, then refined and usually bound to a carrier so the body can take it up.
The silicon ultimately comes from silicon dioxide in sand or from a mined silicate. Alternatively, plant-sourced routes start from silica-accumulating plants such as Equisetum or rice hulls.
Silica is fused with sodium carbonate to give sodium silicate, or reacted to a silicon alkoxide such as tetraethyl orthosilicate. Either gives a soluble starting point that raw quartz cannot provide.
The silicate or alkoxide is hydrolysed under controlled pH and dilution to release monomeric orthosilicic acid. Control here is the whole difficulty: too concentrated and the monomer immediately condenses into silica gel.
Ion exchange strips sodium or the alcohol released from an alkoxide, and the solution is filtered. Residual solvent and alkali specifications are set at this step.
Choline chloride is added to hold the monomer in solution for the ch-OSA form, and the finished liquid is assayed for total silicon and for the monomeric fraction, usually by molybdate colorimetry or by ICP.
The stabilised concentrate is filled into dropper bottles or liquid capsules. Shelf life is governed by how long the monomer stays out of the polymerised state, so storage conditions are part of the specification.
Getting Orthosilicic Acid (ch-OSA) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- A 12-week randomised, double-blind, placebo-controlled multicentre study evaluated choline-stabilised orthosilicic acid against placebo for joint comfort and mobility measures in adults with age-related joint wear.Randomised trial. Geusens et al., 2017 (BMC Musculoskeletal Disorders). PMID 28056936 ↗
- An exploratory randomised, double-blind study of choline-stabilised orthosilicic acid in adults receiving dental implant care, reporting local tissue measures; the authors present it as exploratory rather than confirmatory, and the endpoints are measures rather than clinical outcomes.Randomised trial. Teughels et al., 2021 (BMC Oral Health). PMID 34587941 ↗
- Choline-stabilised orthosilicic acid was reported to partially reduce long-term femoral bone loss in an aged ovariectomised rodent model; a rodent result and not a human outcome.Animal study. Calomme et al., 2006 (Calcified Tissue International). PMID 16604283 ↗
- The review positions silicon as an under-recognised micronutrient involved in normal bone matrix formation and summarises the human and animal literature; it is a narrative synthesis, not new data.Narrative review. Rondanelli et al., 2021 (Experimental Biology and Medicine). PMID 33715532 ↗
- The review compares the chemical forms of silicon available for skin and hair use and discusses what has and has not been demonstrated for each; it is a narrative review and does not rank a form as superior on outcome data.Narrative review. Araujo et al., 2016 (Anais Brasileiros de Dermatologia). PMID 27438201 ↗
These are the studies our verdict leans on, chosen from the 5 we read for Orthosilicic Acid (ch-OSA). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.